Hazte socio de la SAMFyC

Última publicación SAMFyC: Actualización en MF y APS

 

AULA VIRTUAL SAMFyC

Aula de formación virtual de SAMFyC

SAMFyC CONGRESOS

Historico de Comunicaciones
presentadas a los Congresos
Andaluces de MFyC (SAMFyC), desde 2008.


* * * * * * * * * * * * * * * * * * * * * * * * *

Información Socios

Ofertas de Trabajo
Ofertas de Trabajo SOCIOS SAMFYC

¡Actualiza tus datos!
Actualiza tus datos

 

Buscador de Contenidos

Sociedades Federadas

Medicina Familiar y Comunitaria

Sociedades Científicas de Medicina Familiar y Comunitaria

Enlaces de Interés

Consulte Nuestros Enlaces.
Enlaces de Interés

Acceso Socios



 

Buscador de publicaciones externas y alertas bibliográficas

Octubre 2014 PDF Imprimir E-mail
Miércoles, 05 de Noviembre de 2014 00:00

<< Volver

 

SELECCIÓN DE REFERENCIAS BIBLIOGRÁFICAS DE LO PUBLICADO EN RELACIÓN CON ATENCIÓN PRIMARIA

Selección realizada por Antonio Manteca González

 

ANNALS OF INTERNAL MEDICINE

Kroenke K. A practical and evidence-based approach to common symptoms: a narrative review. Ann Intern Med 2014;161:579-586 [R,II]
25329205             R/C

ABORDAJE DE LOS SÍNTOMAS COMUNES PRÁCTICO Y BASADO EN LA EVIDENCIA: REVISIÓN NARRATIVA

 

LeFevre ML; U.S. Preventive Services Task Force. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:587-593 [M,II]

25155419             R/C

CONSEJO CONDUCTUAL PARA PROMOVER DIETA SANA Y ACTIVIDAD FÍSICA PARA LA PREVENCIÓN DE LA ENFERMEDAD CARDIOVASCULAR EN ADULTOS CON FACTORES DE RIESGO CARDIOVASCULAR: DECLARACIÓN DE RECOMENDACIÓN DEL USPSTF

 

Lin JS, O'Connor EA, Evans CV, Senger CA, Rowland MG, Groom HC. Behavioral counseling to promote a healthy lifestyle for cardiovascular disease prevention in persons with cardiovascular risk factors: an updated systematic evidence review for the U.S. Preventive Services Task Force [Internet] [M,II]

25232633             R/C

CONSEJO CONDUCTUAL PARA PROMOVER DIETA SANA Y ACTIVIDAD FÍSICA PARA LA PREVENCIÓN DE LA ENFERMEDAD CARDIOVASCULAR EN ADULTOS CON FACTORES DE RIESGO CARDIOVASCULAR: REVISIÓN ACTUALIZADA  SISTEMÁTICA DE LA EVIDENCIA PARA EL USPSTF

 

ATENCION PRIMARIA

Sempere E, Salazar J, Palop V, Vicens C. Evolución de la utilización de antidepresivos, ansiolíticos e hipnóticos en la Comunitat Valenciana. Período 2000-2010. Aten Primaria 2014;46:416-425 [S,I]

24559729             R/C

EVOLUCIÓN DE LA UTILIZACIÓN DE ANTIDEPRESIVOS, ANSIOLÍTICOS E HIPNÓTICOS EN LA COMUNITAT VALENCIANA

 

Miqueleiz E, Lostao L, Ortega P, Santos JM, Astasio P, Regidor E. Patrón socioeconómico en la alimentación no saludable en niños y adolescentes en España. Aten Primaria 2014;46:433-439 [T,I]

24656757             R/C

PATRÓN SOCIOECONÓMICO EN LA ALIMENTACIÓN NO SALUDABLE EN NIÑOS Y ADOLESCENTES EN ESPAÑA

 

Mata P, Alonso R, Ruíz-Garcia A, Díaz-Díaz JL, González N, Gijón-Conde T, et al. Hiperlipidemia familiar combinada: documento de consenso. Aten Primaria 2014;46:440-446 [M,II]

25034722             R/C

HIPERLIPIDEMIA FAMILIAR COMBINADA: DOCUMENTO DE CONSENSO

 

BRITISH JOURNAL OF PSYCHIATRY

Rüsch N, Zlati A, Black G, Thornicroft G. Does the stigma of mental illness contribute to suicidality? Br J Psychiatry 2014;205:257-259 [AO,I]

25274313

¿CONTRIBUYE EL ESTIGMA DE LA ENFERMEDAD MENTAL A LA TENDENCIA AL SUICIDIO?

 

Cuijpers P, Koole SL, van Dijke A, Roca M, Li J, Reynolds CF 3rd. Psychotherapy for subclinical depression: meta-analysis. Br J Psychiatry 2014;205:268-274 [M,II]

25274315             R/C

PSICOTERAPIA PARA LA DEPRESIÓN SUBCLÍNICA: METAANÁLISIS

 

Kõlves K, De Leo D. Suicide rates in children aged 10-14 years worldwide: changes in the past two decades. Br J Psychiatry 2014;205:283-285 [S,II]

25104833             R/C

TASAS DE SUICIDIO EN NIÑOS ENTRE 10 Y 14 AÑOS EN EL ÁMBITO MUNDIAL: CAMBIOS EN LAS ÚLTIMAS DOS DÉCADAS

 

Galéra C, Pingault JB, Michel G, Bouvard MP, Melchior M, Falissard B, et al. Clinical and social factors associated with attention-deficit hyperactivity disorder medication use: population-based longitudinal study. Br J Psychiatry 2014;205:291-297 [S,II]

25104834             R/C

FACTORES CLÍNICOS Y SOCIALES ASOCIADOS CON EL USO DE MEDICACIÓN PARA EL TRASTORNO DE HIPERACTIVIDAD Y DÉFICIT DE ATENCIÓN: ESTUDIO POBLACIONAL LONGITUDINAL

 

BRITISH MEDICAL JOURNAL

Crawford MJ, MacLaren T, Reilly JG. Are mood stabilisers helpful in treatment of borderline personality disorder? BMJ 2014;349:g5378 [R,I]

25228296

¿SON ÚTILES LOS ESTABILIZADORES DEL ÁNIMO EN EL TRATAMIENTO DEL TRASTORNO LÍMITE DE LA PERSONALIDAD?

 

Zhang C, Tobias DK, Chavarro JE, Bao W, Wang D, Ley SH, et al. Adherence to healthy lifestyle and risk of gestational diabetes mellitus: prospective cohort study. BMJ 2014;349:g5450 [S,I]

25269649             R/C

CUMPLIMIENTO DE HÁBITOS DE VIDA SALUDABLES Y RIESGO DE DIABETES MELLITUS GESTACIONAL: ESTUDIO PROSPECTIVO DE COHORTE

 

Tricco AC, Ashoor HM, Antony J, Beyene J, Veroniki AA, Isaranuwatchai W, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ 2014;349:g5459 [M,II]

25274009             R/C

SEGURIDAD, EFECTIVIDAD Y RENTABILIDAD DE LA INSULINA DE LARGA DURACIÓN FRENTE A LA DE DURACIÓN INTERMEDIA PARA PACIENTES CON DIABETES TIPO 1: REVISIÓN SISTEMÁTICA Y METAANÁLISIS EN RED

 

Currie CJ, Berni E, Jenkins-Jones S, Poole CD, Ouwens M, Driessen S, et al. Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis. BMJ 2014;349:g5493 [S,I]

25249162             R/C

FRACASO DEL TRATAMIENTO ANTIBIÓTICO EN CUATRO INFECCIONES COMUNES EN LA ATENCIÓN PRIMARIA EN R.U. ENTRE 1991 Y 2012: ANÁLISIS LONGITUDINAL

 

Meltzer SJ. Unhealthy lifestyles and gestational diabetes. BMJ 2014;349:g5549 [AO,I]

25270049

HÁBITOS DE VIDA POCO SALUDABLES Y DIABETES GESTACIONAL

 

Whittle J, Fyfe R, Iles RD, Wildfong J. Patients are overoptimistic about PCI. BMJ 2014;348:g5613 [AO,I]

25234050

LOS PACIENTES SON OPTIMISTAS EN EXCESO RESPECTO A LAS INTERVENCIONES CORONARIAS PERCUTÁNEAS

 

Hoffman JR, Kanzaria HK. Intolerance of error and culture of blame drive medical excess. BMJ 2014;349:g5702 [R,I]

25315302

LA INTOLERANCIA AL ERROR Y  LA CULTURA DE LA CULPA LLEVAN AL EXCESO MÉDICO

 

Fokkens WJ, Hoffmans R, Thomas M. Avoid prescribing antibiotics in acute rhinosinusitis. BMJ 2014;349:g5703 [R,II]

25353368

EVITE PRESCRIBIR ANTIBIÓTICOS EN LA RINOSINUSITIS AGUDA

 

Naci H, Dias S, Ades AE. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ 2014;349:g5741 [M,II]

25281681             R/C

SESGO POR PATROCINIO DE LA INDUSTRIA EN LOS HALLAZGOS DE LA INVESTIGACIÓN: METAANÁLISIS EN RED DE LA REDUCCIÓN DE COLESTEROL LDL EN LOS ENSAYOS ALEATORIZADOS SOBRE ESTATINAS

 

Hargraves I, Montori VM. Decision aids, empowerment, and shared decision making. BMJ 2014;349:g5811 [AO,I]

25255800

AYUDAS A LA DECISIÓN, EMPODERAMIENTO Y TOMA COMPARTIDA DE DECISIONES

 

Powell J, O'Hara J, Wilson JA. Are persistent throat symptoms atypical features of gastric reflux and should they be treated with proton pump inhibitors? BMJ 2014;349:g5813 [R,I]

25300569

¿SON LOS SÍNTOMAS PERSISTENTES DE GARGANTA CARACTERÍSTICAS ATÍPICAS DEL REFLUJO GÁSTRICO Y SE DEBERÍAN TRATAR CON IBP?

 

Wood JM, Athanasiadis T, Allen J. Laryngitis. BMJ 2014;349:g5827 [R,I]

25300640

LARINGITIS

 

McCarthy FP, O'Brien U, Kenny LC. The management of teenage pregnancy. BMJ 2014;349: g5887 [R,I]

25319232

MANEJO DEL EMBARAZO ADOLESCENTE

 

Arie S, Mahony C. Should patient groups be more transparent about their funding? BMJ 2014;349:g5892 [AO,I]

25266116

¿DEBERÍAN LAS ASOCIACIONES DE PACIENTES SER MÁS TRANSPARENTES RESPECTO A SU FINANCIACIÓN?

 

Mars B, Heron J, Crane C, Hawton K, Lewis G, Macleod J, et al. Clinical and social outcomes of adolescent self harm: population based birth cohort study. BMJ 2014;349:g5954 [S,I]

25335825             R/C

RESULTADOS CLÍNICOS Y SOCIALES DE LAS AUTOLESIOENS EN ADOLESCENTES: ESTUDIO DE COHORTE POBLACIONAL DESDE EL NACIMIENTO

 

Coenen S, Goossens H. Antibiotic treatment failure in primary care. BMJ 2014;349:g5970 [AO,I]

25277996

FRACASO DEL TRATAMIENTO ANTIBIÓTICO EN ATENCIÓN PRIMARIA

 

Michaëlsson K, Wolk A, Langenskiöld S, Basu S, Warensjö Lemming E, Melhus H, et al. Milk intake and risk of mortality and fractures in women and men: cohort studies. BMJ 2014;349:g6015 [S,I]

25352269             R/C

CONSUMO DE LECHE Y RIESGO DE MORTALIDAD Y FRACTURAS EN MUJERES Y HOMBRES: ESTUDIOS DE COHORTE

 

Godlee F. Optimism and consent to treatment. BMJ 2014;349:g6118 [AO,I]

OPTIMISMO Y CONSENTIMIENTO DE TRATAMIENTO

 

Roman S, Kahrilas PJ. The diagnosis and management of hiatus hernia. BMJ 2014;349:g6154 [R,I]

25341679

DIAGNÓSTICO Y TRATAMIENTO DE LA HERNIA DE HIATO

 

Fralick M, Macdonald EM, Gomes T, Antoniou T, Hollands S, Mamdani MM, et al; Canadian Drug Safety and Effectiveness Research Network (CDSERN). Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 2014;349:g6196 [CC,I]

25359996             R/C

COTRIMOXAZOL Y MUERTE SÚBITA EN PACIENTES QUE RECIBEN INHIBIDORES DEL SISTEMA RENINA-ANGIOTENSINA: ESTUDIO POBLACIONAL

 

House A. Self harm in young people. BMJ 2014;349:g6204 [AO,I]

25335918

AUTOLESIONES EN JÓVENES

 

Schooling CM. Milk and mortality. BMJ 2014;349:g6205 [AO,I]

25352270

LECHE Y MORTALIDAD

 

Warttig S, Ward S, Rogers G; Guideline Development Group. Diagnosis and management of gallstone disease: summary of NICE guidance. BMJ 2014;349:g6241 [M,II]

25360037

DIAGNÓSTICO Y TRATAMIENTO DE LA LITIASIS BILIAR

 

Etminan M, Brophy JM. Antibiotics and sudden death in adults taking renin-angiotensin system blockers. BMJ 2014;349:g6242 [AO,I]

25360034

ANTIBIÓTICOS Y MUERTE SÚBITA EN ADULTOS QUE TOMAN BLOQUEANTES DEL SISTEMA RENINA-ANGIOTENSINA

 

Godlee F. Ebola: will enlightened self interest spur us to act? BMJ 2014;349:g6254

ÉBOLA: ¿NOS INCITARÁ A ACTUAR EL INTERÉS PROPIO?

 

Gillam S. Future shape of general practice in England. BMJ 2014;349:g6268 [AO,I]

25335888

FORMA FUTURA DE LA MEDICINA GENERAL EN INGLATERRA

 

Rade JJ. Routine thienopyridine pretreatment for acute coronary syndrome without ST elevation. BMJ 2014;349:g6282  [AO,I]

PRETRATAMIENTO DE RUTINA CON TIENOPIRIDINA EN EL SÍNDROME CORONARIO AGUDO SIN ELEVACIÓN DE ST

 

Novel drugs and drug combinations for treating tuberculosis. BMJ 2014;349:g6563 [R,I]

25365964

NUEVOS FÁRMACOS Y COMBINACIONES DE FÁRMACOS PARA TRATAR LA TUBERCULOSIS

 

CANADIAN MEDICAL ASSOCIATION JOURNAL

Juurlink DN. The cardiovascular safety of azithromycin. CMAJ 2014;186:1127-1128 [AO,I]

25096666

SEGURIDAD CARDIOVASCULAR DE LA AZITROMICINA

 

Fournier JP, Yin H, Yu OH, Azoulay L. Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus. CMAJ 2014;186:1138-1145 [T,I]

25246411             R/C

METFORMINA Y NIVELES BAJOS DE TSH EN PACIENTES CON DIABETES MELLITUS TIPO 2

 

Parameswaran GI, Sethi S. Long-term macrolide therapy in chronic obstructive pulmonary disease. CMAJ 2014;186:1148-1152 [R,I]

25096664

TERAPIA DE LARGA DURACIÓN CON MACRÓLIDOS EN LA EPOC

 

Tricco AC, Antony J, Ivers NM, Ashoor HM, Khan PA, Blondal E, et al. Effectiveness of quality improvement strategies for coordination of care to reduce use of health care services: a systematic review and meta-analysis. CMAJ 2014;186:E568-E578 [M,II]

25225226             R/C

EFECTIVIDAD DE LAS ESTRATEGIAS DE MEJORA DE LA CALIDAD EN LA COORDINACIÓN DE LA ATENCIÓN PARA REDUCIR EL USO DE LOS SERVICIOS DE ATENCIÓN SANITARIA: REVISIÓN SISTEMÁTICA Y METAANÁLISIS

 

Mavragani CP, Moutsopoulos HM. Sjögren syndrome. CMAJ 2014;186:E579-E586 [R,I]

24566651

SÍNDROME DE SJÖGREN

 

Sharma M, Tan DH. HIV pre-exposure prophylaxis. CMAJ 2014;186:E588 [AO,I]

25096663

PROFILAXIS PREEXPOSICIÓN AL VIH

 

CIRCULATION

 Kelly PJ. Preventing the rise of atrial fibrillation-related stroke in populations: a call to action. Circulation 2014;130:1221-1222 [AO,I]

25208552

PREVENIR EL AUMENTO DE ICTUS RELACIONADO CON FIBRILACIÓN AURICULAR EN LAS POBLACIONES: LLAMADA A LA ACCIÓN

 

Yiin GS, Howard DP, Paul NL, Li L, Luengo-Fernandez R, Bull LM, et al; Oxford Vascular Study.

Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study. Circulation 2014;130:1236-1244 [S,I]

25208551             R/C

INCIDENCIA ESPECÍFICA POR EDAD, RESULTADOS, COSTO Y PROYECCIÓN DE CARGA FUTURA DE ACONTECIMIENTOS EMBÓLICOS VASCULARES RELACIONADOS CON LA FIBRILACIÓN AURICULAR: ESTUDIO POBLACIONAL

 

Maron BJ, Friedman RA, Kligfield P, Levine BD, Viskin S, Chaitman BR, et al; American Heart Association Council on Clinical Cardiology, Advocacy Coordinating Committee, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Surgery and Anesthesia, Council on Epidemiology and Prevention, Council on Functional Genomics and Translational Biology, Council on Quality of Care and Outcomes Research, and American College of Cardiology. Assessment of the 12-lead ECG as a screening test for detection of cardiovascular disease in healthy general populations of `young people (12-25 years of age): a scientific statement from the American Heart Association and the American College of Cardiology. Circulation 2014;130:1303-1334 [M,II]

25223981

VALORACIÓN DEL ECG DE 12 DERIVACIONES COMO PRUEBA DE CRIBAJE PARA LA DETECCIÓN DE ENFERMEDAD CARDIOVASCULAR EN POBLACIONES GENERALES SANAS DE JÓVENES (ENTRE 12 Y 25 AÑOS): DECLARACIÓN CIENTÍFICA DE LA AHA Y EL ACC

 

Maahs DM, Daniels SR, de Ferranti SD, Dichek HL, Flynn J, Goldstein BI, et al; American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council for High Blood Pressure Research, and Council on Lifestyle and Cardiometabolic Health. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation 2014;130:1532-1558 [M,II]

25170098

FACTORES DE RIESGO DE ENFERMEDAD CARDIOVASCULAR EN JÓVENES CON DIABETES MELLITUS: DECLARACIÓN CIENTÍFICA DE LA AHA

 

Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, et al; American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2014;130:1636-1661 [M,II]

25246013

SÍNDROME POSTROMBÓTICO: PREVENCIÓN BASADA EN LA EVIDENCIA, DIAGNÓSTICO Y ESTRATEGIAS DE TRATAMIENTO: DECLARACIÓN CIENTÍFICA DE LA AHA

 

Fonarow GC. Diabetes medications and heart failure: recognizing the risk.

Circulation 2014 [Epub ahead of print] [AO,I]

25189212             R/C

MEDICACIONES PARA LA DIABETES E INSUFICIENCIA CARDIACA: RECONOCER EL RIESGO

 

Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al; for the SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR - TIMI 53 randomized trial. Circulation 2014 [Epub ahead of print] [EC,II]

25189213             R/C

INSUFICIENCIA CARDIACA, SAXAGLIPTINA Y DIABETES MELLITUS: OBSERVACIONES DEL ENSAYO ALEATORIZADO SAVOR-TIMI 53

 

Harris WS, Shearer GC. Omega-6 fatty acids and cardiovascular disease: friend or foe? Circulation 2014 [Epub ahead of print] [AO,I]

25161044             R/C

ÁCIDOS GRASOS OMEGA 6 Y ENFERMEDAD CARDIOVASCULAR: ¿AMIGO O ENEMIGO?

 

DIABETES CARE

Phillips LS, Ratner RE, Buse JB, Kahn SE. We can change the natural history of type 2 diabetes. Diabetes Care 2014;37:2668-2676 [R,I]

25249668             R/C

PODEMOS CAMBIAR LA HISTORIA NATURAL DE LA DIABETES TIPO 2

 

Leiter LA, Carr MC, Stewart M, Jones-Leone A, Scott R, Yang F, et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist Albiglutide versus Sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care 2014;37:2723-2730 [EC,I]

25048383             R/C

EFICACIA Y SEGURIDAD DEL AGONISTA DEL RECEPTOR GLP-1 ALBIGLUTIDA FRENTE A LA SITAGLIPTINA EN PACIENTES CON DIABETES TIPO 2 Y ALTERACIÓN RENAL: ESTUDIO ALEATORIZADO EN FASE III

 

Driskell OJ, Holland D, Waldron JL, Ford C, Scargill JJ, Heald A, et al. Reduced testing frequency for glycated hemoglobin, HbA1c, is associated with deteriorating diabetes control. Diabetes Care 2014;37:2731-2737 [T,II]

25249670             R/C

LA FRECUENCIA REDUCIDA DE PRUEBAS DE LA HBA1C SE ASOCIA CON DETERIORO EN EL CONTROL DE LA DIABETES

 

Delahanty LM, Pan Q, Jablonski KA, Aroda VR, Watson KE, Bray GA, et al; Diabetes Prevention Program Research Group. Effects of weight loss, weight cycling, and weight loss maintenance on diabetes incidence and change in cardiometabolic traits in the Diabetes Prevention Program. Diabetes Care 2014;37:2738-2745 [S,I]

25024396             R/C

EFECTOS DE LA PÉRDIDA DE PESO, PESO CÍCLICO Y MANTENIMIENTO DE LA PÉRDIDA DE PESO SOBRE LA INCIDENCIA DE DIABETES Y CAMBIO EN LOS RASGOS METABÓLICOS EN EL PROGRAMA DE PREVENCIÓN DE DIABETES

 

Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD; EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014;37:2755-2762 [EC,II]

25078900             R/C

300 UNIDADES/ML DE LA NUEVA INSULINA GLARGINA FRENTE A 100 UNIDADES/ML DE GLARGINA EN PERSONAS CON DIABETES TIPO 2 QUE USAN INSULINA BASAL Y A LA HORA DE LAS COMIDAS: CONTROL DE GLUCOSA E HIPOGLUCEMIA EN UN ENSAYO ALEATORIZADO CONTROLADO DE 6 MESES (EDITION 1)

 

Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, et al; 4B Study Group. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 2014;37:2763-2773 [EC,II]

25011946             R/C

AGONISTA DEL RECEPTOR GLP-1 O INSULINA EN BOLO CON INSULINA BASAL OPTIMIZADA EN LA DIABETES TIPO 1

 

Cox AJ, Hsu FC, Freedman BI, Herrington DM, Criqui MH, Carr JJ, et al. Contributors to mortality in high-risk diabetic patients in the Diabetes Heart study. Diabetes Care 2014;37:2798-2803 [S,II]

24989706             R/C

CONTRIBUYENTES A LA MORTALIDAD EN PACIENTES DIABÉTICOS DE ALTO RIESGO EN EL ESTUDIO  DIABETES HEART

 

de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care 2014;37:2843-2863 [M,II]

25114297

DIABETES MELLITUS TIPO 1 Y ENFERMEDAD CARDIOVASCULAR: INFORME DE UNA CONFERENCIA DE CONSENSO DE LA ADA

 

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care 2014;37:2864-2883 [M,II]

25249672             R/C

ENFERMEDAD RENAL DIABÉTICA: INFORME DE UNA CONFERENCIA DE CONSENSO DE LA ADA

 

Avogaro A, Fadini GP. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care 2014;37:2884-2894 [R,I]

25249673             R/C

LOS EFECTOS DE LA INHIBICIÓN DPP-4 SOBRE LAS COMPLICACIONES MICROVASCULARES DE LA DIABETES

 

DRUGS

Taher AT, Cappellini MD. Management of non-transfusion-dependent thalassemia: a practical guide. Drugs 2014;74:1719-1729 [R,I]

25255924             R/C

MANEJO DE LA TALASEMIA NO DEPENDIENTE DE TRANSFUSIÓN: GUÍA PRÁCTICA

 

Fardet L1, Fève B. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs 2014;74:1731-1745 [R,I]

25204470             R/C

TERAPIA SISTÉMICA CON CORTICOIDES: REVISIÓN DE SUS EFECTOS ADVERSOS METABÓLICOS Y CARDIOVASCULARES

 

Gallagher D, Herrmann N. Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy? Drugs 2014;74:1747-1755 [R,I]

25239267             R/C

FÁRMACOS ANTIEPILÉPTICOS PARA EL TRATAMIENTO DE LA AGITACIÓN Y LA AGRESIÓN EN LA DEMENCIA: ¿TIENEN SU LUGAR EN EL TRATAMIENTO?

 

Scott LJ. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 2014;74:1769-1784 [R,I]

25274537             R/C

EMPAGLIFLOZINA: REVISIÓN DE SU USO EN PACIENTES CON DIABETES MELLITUS TIPO 2

 

Greig SL1, McKeage K. Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence. Drugs 2014;74:1785-1800 [R,I]

25270377             R/C

ETEXILATO DE DABIGATRÁN: REVISIÓN DE SU USO EN EL TRATAMIENTO DEL TROMBOEMBOLISMO VENOSO Y EN LA PREVENCIÓN DE LA RECURRENCIA DEL TROMBOEMBOLISMO VENOSO

 

Keating GM. Tiotropium respimat(®) soft mist™ inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs 2014;74:1801-1816 [R,I]

25300412             R/C

INHALADOR DE NEBULIZACIÓN SUAVE TIOTROPIO RESPIMAT: REVISIÓN DE SU USO EN LA EPOC

 

Bonovas S. Statins: do they have a potential role in cancer prevention and modifying cancer-related outcomes? Drugs 2014;74:1841-1848 [R,I]

25288321             R/C

ESTATINAS: ¿TIENEN UN PAPEL POTENCIAL EN LA PREVENCIÓN DEL CÁNCER Y EN LA MODIFICACIÓN DE RESULTADOS RELACIONADOS CON EL CÁNCER?

 

Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74:1891-1925 [R,I]

25315029             R/C

BEVACIZUMAB: REVISIÓN DE SU USO EN EL CÁNCER AVANZADO

 

McKeage K. Linagliptin: an update of its use in patients with type 2 diabetes mellitus. Drugs 2014;74:1927-1946 [R,I]

25297911             R/C

LINAGLIPTINA: ACTUALIZACIÓN DE SU USO EN PACIENTES CON DIABETES MELLITUS TIPO 2

 

Scott LJ. Rifaximin: a review of its use in reducing recurrence of overt hepatic encephalopathy episodes. Drugs 2014 [Epub ahead of print] [R,I]

25352391             R/C

RIFAXIMINA: REVISIÓN DE SU USO PARA REDUCIR LA RECURRENCIA DE EPISODIOS DE ENCEFALOPATÍA HEPÁTICA MANIFIESTA

 

EUROPEAN HEART JOURNAL

Wong CM, Hawkins NM, Petrie MC, Jhund PS, Gardner RS, Ariti CA, et al; MAGGIC Investigators. Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). Eur Heart J 2014;35:2714-2721 [M,II]

24944329             R/C

INSUFICIENCIA CARDIACA EN PACIENTES JÓVENES: METAANÁLISIS MAGGIC

 

Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al; Authors/Task Force members. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733-2779 [M,II]

25173338

GUÍAS ESC PARA EL DIAGNÓSTICO Y MANEJO DE LA MIOCARDIOPATÍA HIPERTRÓFICA: GRUPO DE TRABAJO SOBRE MIOCARDIOPATÍA HIPERTRÓFICA DE LA ESC

 

FAMILY MEDICINE

Liaw W, Bazemore A, Mishori R, Diller P, Bardella I, Chang N. The financial health of global health programs. Fam Med 2014;46:672-678 [T,I]

25275276             R/C

LA SALUD FINANCIERA DE LOS PROGRAMAS SANITARIOS MUNDIALES

 

Doohan NC, Derbew M, McQueen KA. Solutions for the global surgical crisis: the role of family medicine in surgery, obstetrics, and anesthesia. Fam Med 2014;46:679-684 [AO,I]

25275277

SOLUCIONES PARA LA CRISIS MUNDIAL DE LA CIRUGÍA: PAPEL DE LA MEDICINA DE FAMILIA EN LA CIRUGÍA, OBSTETRICIA Y ANESTESIA

 

Kozakowski SM, Crosley PW, Bentley A. Entry of US medical school graduates into family medicine residencies: 2013--2014. Fam Med 2014;46:696-700 [T,II]

25275280             R/C

ENTRADA DE LICENCIADOS EN MEDICINA EN EE UU A LA RESIDENCIA DE MEDICINA DE FAMILIA: 2013-2014

 

Kozakowski SM, Crosley PW, Bentley A. Results of the 2014 National Resident Matching Program®: family medicine. Fam Med 2014;46:701-706 [T,II]

25275281             R/C

RESULTADOS DEL PROGRAMA NACIONAL DE SELECCIÓN DE RESIDENTES 2014: MEDICINA DE FAMILIA

 

FAMILY PRACTICE

Murphy ME, Fahey T, Smith SM. Computer-based clinical decision support for general practitioners. Fam Pract 2014;31:497-498 [AO,I]

25096276

AYUDA A LA DECISIÓN CLÍNICA MEDIANTE ORDENADOR PARA MÉDICOS GENERALES

 

Westert GP, Jeurissen PP, Assendelft WJ. Why Dutch general practitioners do not put the squeeze on access to hospital care? Fam Pract 2014;31:499-501 [AO,I]

24919783

¿POR QUÉ LOS MÉDICOS GENERALES HOLANDESES NO LE SACAN EL JUGO AL ACCESO A LA ATENCIÓN HOSPITALARIA?

 

van Loenen T, van den Berg MJ, Westert GP, Faber MJ. Organizational aspects of primary care related to avoidable hospitalization: a systematic review. Fam Pract 2014;31:502-516 [M,II]

25216664             R/C

ASPECTOS ORGANIZATIVOS DE LA ATENCIÓN PRIMARIA RELACIONADOS CON LA HOSPITALIZACIÓN EVITABLE: REVISIÓN SISTEMÁTICA

 

Viniol A, Keunecke C, Biroga T, Stadje R, Dornieden K, Bösner S, et al. Studies of the symptom abdominal pain-a systematic review and meta-analysis. Fam Pract 2014;31:517-529 [M,I]

24987023             R/C

ESTUDIOS DEL SÍNTOMA DOLOR ABDOMINAL-REVISIÓN SISTEMÁTICA Y METAANÁLISIS

 

Llor C, Plana-Ripoll O, Moragas A, Bayona C, Morros R, Pera H, et al. Is C-reactive protein testing useful to predict outcome in patients with acute bronchitis? Fam Pract 2014;31:530-537 [EC,I]

25037854             R/C

¿ES LA PRUEBA DE LA PROTEÍNA C REACTIVA ÚTIL PARA PREDECIR EL RESULTADO EN PACIENTES CON BRONQUITIS AGUDA?

 

Wammes JJ, Jeurissen PP, Verhoef LM, Assendelft WJ, Westert GP, Faber MJ. Is the role as gatekeeper still feasible? A survey among Dutch general practitioners. Fam Pract 2014;31:538-544 [T,I]

25135953             R/C

¿ES FACTIBLE TODAVÍA EL PAPEL DE REGULADOR DE LA ENTRADA? ENCUESTA ENTRE MÉDICOS GENERALES HOLANDESES

 

Parker L, Moran GM, Roberts LM, Calvert M, McCahon D. The burden of common chronic disease on health-related quality of life in an elderly community-dwelling population in the UK. Fam Pract 2014;31:557-563 [T,I]

24987022             R/C

LA CARGA DE ENFERMEDAD CRÓNICA COMÚN SOBRE LA CALIDAD DE VIDA RELACIONADA CON LA SALUD EN UNA POBLACIÓN DE ANCIANOS RESIDENTES EN LA COMUNIDAD EN R.U.

 

Goenee MS, Donker GA, Picavet C, Wijsen C. Decision-making concerning unwanted pregnancy in general practice. Fam Pract 2014;31:564-570 [T,I]

24997249             R/C

TOMA DE DECISIONES RESPECTO AL EMBARAZO NO DESEADO EN MEDICINA GENERAL

 

Eveleigh R, Grutters J, Muskens E, Oude Voshaar R, van Weel C, Speckens A, et al. Cost-utility analysis of a treatment advice to discontinue inappropriate long-term antidepressant use in primary care. Fam Pract 2014;31:578-584 [CE,I]

25121977             R/C

ANÁLISIS DE RENTABILIDAD DE UN CONSEJO DE TRATAMIENTO PARA SUSPENDER EL USO INAPROPIADO DE ANTIDEPRESIVOS A LARGO PLAZO EN ATENCIÓN PRIMARIA

 

Vorilhon P, Picard V, Marty L, Vaillant Roussel H, Llorca PM, Laporte C. Attitudes of family physicians towards adolescent cannabis users: a qualitative study in France. Fam Pract 2014;31:585-591 [C,I]

24939655             R/C

ACTITUDES DE LOS MÉDICOS DE FAMILIA HACIA LOS USUARIOS ADOLESCENTES DE CANABIS: ESTUDIO CUALITATIVO EN FRANCIA

 

Asiedu GB, Eustace RW, Eton DT, Radecki Breitkopf C. Coping with colorectal cancer: a qualitative exploration with patients and their family members. Fam Pract 2014;31:598-606 [C,I]

25080507             R/C

AFRONTAR EL CÁNCER COLORRECTAL: EXPLORACIÓN CUALITATIVA CON PACIENTES Y SUS FAMILIARES

 

GUT

Sung JJ. Is aspirin for colorectal cancer prevention on the prime time yet? Gut 2014;63:1691-1692 [AO,I]

24821617

¿ESTÁ LA ASPIRINA TODAVÍA EN PRIMER PLANO PARA LA PREVENCIÓN DEL CÁNCER COLORRECTAL?

 

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Boling PA. Managing posthospital care transitions for older adults: challenges and opportunities. JAMA 2014;312:1303-1304 [AO,I]

25268436

MANEJO DE LAS TRANSICIONES DE CUIDADOS POSTHOSPITALARIOS EN ANCIANOS: RETOS Y OPORTUNIDADES

 

Frieden TR, Brudney KF, Harries AD. Global tuberculosis: perspectives, prospects, and priorities. JAMA 2014;312:1393-1394 [AO,I]

25188638

TUBERCULOSIS EN EL MUNDO: PERSPECTIVAS,EXPECTATIVAS Y PRIORIDADES

 

Treanor JJ. Expanding the options for confronting pandemic influenza. JAMA 2014;312:1401-1402 [AO,I]

25291574

EXPANDIR LAS OPCIONES PARA AFRONTAR LA GRIPE PANDÉMICA

 

Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA 2014;312:1677-1684 [R,I]

25335150             R/C

DIAGNÓSTICO Y MANEJO DE LAS INFECCIONES DE VÍAS URINARIAS BAJAS EN EL ÁMBITO AMBULATORIO: REVISIÓN

 

JAMA INTERNAL MEDICINE

Feldman S. Human papillomavirus testing for primary cervical cancer screening: is it time to abandon Papanicolaou testing? JAMA Intern Med 2014;174:1539-1540 [AO,I]

25069413

PRUEBA DEL VIRUS DEL PAPILOMA HUMANO PARA EL CRIBAJE DE CÁNCER PRIMARIO DE CÉRVIX: ¿ES HORA DE ABANDONAR LA PRUEBA DE PAPANICOLAU?

 

Chiolero A, Rodondi N. Lessons from the Swiss Medical Board recommendation against mammography screening programs. JAMA Intern Med 2014;174:1541-1542 [AO,I]

25154463

LECCIONES DE LA RECOMENDACIÓN DEL CONSEJO MÉDICO SUIZO CONTRA LOS PROGRAMAS DE CRIBAJE MAMOGRÁFICO

 

Mason MK. Looking for trouble-patient preference misdiagnosis and overtesting: a teachable moment. JAMA Intern Med 2014;174:1548-1549 [AO,I]

25110926

BUSCAR LA PREFERENCIA DEL PACIENTE PROBLEMÁTICO POR EL EXCESO DE PRUEBAS Y EL DIAGNÓSTICO DESVIADO: MOMENTO DE ENSEÑANZA

 

Hue TF, Cummings SR, Cauley JA, Bauer DC, Ensrud KE, Barrett-Connor E, et al. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med 2014;174:1550-1557 [EC,II]

25111880             R/C

EFECTO DEL USO DE BIFOSFONATOS SOBRE EL RIESGO DE CÁNCER DE MAMA POSTMENOPÁUSICO: RESULTADOS DE LOS ENSAYOS CLÍNICOS ALEATORIZADOS SOBRE ALENDRONATO Y ÁCIDO ZOLEDRÓNICO

 

Royce TJ, Hendrix LH, Stokes WA, Allen IM, Chen RC. Cancer screening rates in individuals with different life expectancies. JAMA Intern Med 2014;174:1558-1565 [T,II]

25133746             R/C

TASAS DE CRIBADO DE CÁNCER EN INDIVIDUOS CON DIFERENTES EXPECTATIVAS DE VIDA

 

Wang DD, Leung CW, Li Y, Ding EL, Chiuve SE, Hu FB, et al. Trends in dietary quality among adults in the United States, 1999 through 2010. JAMA Intern Med 2014;174:1587-1595 [S,II]

25179639             R/C

TENDENCIAS EN CALIDAD DIETÉTICA ENTRE ADULTOS EN EE UU, DE 1999 A 2010

 

Pasternak B, Svanström H, Melbye M, Hviid A. Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure. JAMA Intern Med 2014;174:1597-1604 [S,I]

25173681             R/C

ASOCIACIÓN DE TRATAMIENTO CON CARVEDILOL FRENTE A SUCCINATO DE METOPROLOL Y MORTALIDAD EN PACIENTES CON INSUFICIENCIA CARDIACA

 

JAMA PSYCHIATRY

Thase ME. Large-scale study suggests specific indicators for combined cognitive therapy and pharmacotherapy in major depressive disorder. JAMA Psychiatry 2014;71:1101-1102 [AO,I]

25142013

UN  ESTUDIO A GRAN ESCALA SUGIERE INDICADORES ESPECÍFICOS PARA LA TERAPIA COGNITIVA COMBINADA Y FARMACOTERAPIA EN EL TRASTORNO DEPRESIVO MAYOR

 

Bernert RA, Turvey CL, Conwell Y, Joiner TE Jr. Association of poor subjective sleep quality with risk for death by suicide during a 10-year period: a longitudinal, population-based study of late life. JAMA Psychiatry 2014;71:1129-1137 [S,I]

25133759             R/C

ASOCIACIÓN ENTRE MALA CALIDAD SUBJETIVA DEL SUEÑO Y RIESGO DE MUERTE POR SUICIDIO DURANTE UN PERIODO DE 10 AÑOS: ESTUDIO LONGITUDINAL POBLACIONAL EN LA VIDA AVANZADA

 

Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, et al. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2014;71:1157-1164 [EC,II]

25142196             R/C

EFECTO DE LA TERAPIA COGNITIVA MÁS MEDICACIÓN ANTIDEPRESIVA FRENTE A ANTIDEPRESIVOS SOLOS SOBRE LA TASA DE RECUPERACIÓN EN EL TRASTORNO DEPRESIVO MAYOR: ENSAYO CLÍNICO ALEATORIZADO

 

MEDICINA CLINICA

Dávila-Arias C, Ocón O, Fernández MF, Arrebola JP, Sánchez MJ, Aneiros J, et al. Factores relacionados con la supervivencia libre de enfermedad en el cáncer de mama. Med Clin (Barc) 2014;143:293-299 [S,I]

24378147             R/C

FACTORES RELACIONADOS CON LA SUPERVIVENCIA LIBRE DE ENFERMEDAD EN EL CÁNCER DE MAMA

 

Puig-Vives M, Osca-Gelis G, Camprubí-Font C, Vilardell ML, Izquierdo A, Marcos-Gragera R. Proporción de cáncer de mama en mujeres de 50 a 69 años de Girona según el método de detección. Med Clin (Barc) 2014;143:300-302 [T,I]

24378145             R/C

PROPORCIÓN DE CÁNCER DE MAMA EN MUJERES DE 50 A 69 AÑOS DE GIRONA SEGÚN EL MÉTODO DE DETECCIÓN

 

Villuendas R, Alcalde O. La ablación en la fibrilación auricular. Med Clin (Barc) 2014;143:303-305 [AO,I]

25002066

LA ABLACIÓN EN LA FIBRILACIÓN AURICULAR

 

Alonso-Coello P, Martínez L. Guías de práctica clínica: viejos y nuevos retos. Med Clin (Barc) 2014;143:306-308 [AO,I]

25023850

GUÍAS DE PRÁCTICA CLÍNICA: VIEJOS Y NUEVOS RETOS

 

Llordés M, Zurdo E, Serra I, Giménez N; en representación del grupo de estudio DVA. Conocimientos, expectativas y preferencias respecto al documento de voluntades anticipadas entre los pacientes de atención primaria. Med Clin (Barc) 2014;143:309-313 [T,I]

25015252

CONOCIMIENTOS, EXPECTATIVAS Y PREFERENCIAS RESPECTO AL DOCUMENTO DE VOLUNTADES ANTICIPADAS ENTRE LOS PACIENTES DE ATENCIÓN PRIMARIA

 

Galicia M, Nogué S, Burillo-Putze G. Diez años de asistencias urgentes a consumidores de cocaína en España. Med Clin (Barc) 2014;143:322-326 [T,I]

24461737             R/C

DIEZ AÑOS DE ASISTENCIAS URGENTES A CONSUMIDORES DE COCAÍNA EN ESPAÑA

 

Forés R, Alzamora MT, Pera G, Torán P, Urrea M, Heras A. Concordancia entre 3 métodos de medición del índice tobillo-brazo para el diagnóstico de arteriopatía periférica. Med Clin (Barc) 2014;143:335-340 [T,I]

24703416             R/C

CONCORDANCIA ENTRE 3 MÉTODOS DE MEDICIÓN DEL ÍNDICE TOBILLO-BRAZO PARA EL DIAGNÓSTICO DE ARTERIOPATÍA PERIFÉRICA

 

Pérula LA, Pulido L, Pérula C, González J, Olaya I, Ruiz R; Grupo corporativo Estudio ATEM-AP. Eficacia de la entrevista motivacional para reducir errores de medicación en pacientes crónicos polimedicados mayores de 65 años: resultados de un ensayo clínico aleatorizado por cluster. Med Clin (Barc) 2014;143:341-348 [EC,II]

24378144             R/C

EFICACIA DE LA ENTREVISTA MOTIVACIONAL PARA REDUCIR ERRORES DE MEDICACIÓN EN PACIENTES CRÓNICOS POLIMEDICADOS MAYORES DE 65 AÑOS: RESULTADOS DE UN ENSAYO CLÍNICO ALEATORIZADO POR CLUSTER

 

Bermudo G, Pomares X, Montón C, Baré M, Monsó E. Utilidad del cuestionario Chronic Obstructive Pulmonary Disease Assessment Test en la enfermedad pulmonar obstructiva crónica con obstrucción grave al flujo aéreo. Med Clin (Barc) 2014;143:349-351 [S,I]

24210982             R/C

UTILIDAD DEL CUESTIONARIO CHRONIC OBSTRUCTIVE PULMONARY DISEASE ASSESSMENT TEST EN LA ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA CON OBSTRUCCIÓN GRAVE AL FLUJO AÉREO

 

Nogales JM. Diagnóstico precoz de la arteriopatía periférica mediante la determinación automática del índice tobillo-brazo. Med Clin (Barc) 2014;143:352-353 [AO,I]

24581838

DIAGNÓSTICO PRECOZ DE LA ARTERIOPATÍA PERIFÉRICA MEDIANTE LA DETERMINACIÓN AUTOMÁTICA DEL ÍNDICE TOBILLO-BRAZO

 

REVISTA ESPAÑOLA DE CARDIOLOGIA

Quiles J, Miralles-Vicedo B. Estrategias de prevención secundaria del síndrome coronario agudo. Rev Esp Cardiol 2014;67:844-848  [R,II]

25262131             R/C

ESTRATEGIAS DE PREVENCIÓN SECUNDARIA DEL SÍNDROME CORONARIO AGUDO

 

Ruilope LM, Arribas F. Hipertensión arterial resistente y denervación renal. Reflexiones tras el estudio Symplicity HTN-3. Rev Esp Cardiol 2014;67:881-882 [AO,I]

25242659             R/C

HIPERTENSIÓN ARTERIAL RESISTENTE Y DENERVACIÓN RENAL. REFLEXIONES TRAS EL ESTUDIO SYMPLICITY HTN-3

 

Rodríguez-Mañero M, Otero-Raviña F, García-Seara J, Zugaza-Gurruchaga L, Rodríguez-García JM, Blanco-Rodríguez R, et al; en nombre de los investigadores del Grupo Barbanza. Seguimiento clínico de una muestra contemporánea de pacientes con fibrilación auricular en tratamiento con digoxina: resultados del estudio AFBAR. Rev Esp Cardiol 2014;67:890-897 [S,I]

24835599             R/C

SEGUIMIENTO CLÍNICO DE UNA MUESTRA CONTEMPORÁNEA DE PACIENTES CON FIBRILACIÓN AURICULAR EN TRATAMIENTO CON DIGOXINA: RESULTADOS DEL ESTUDIO AFBAR

 

Brotons C, Calvo-Bonacho E, Moral I, García-Margallo MT, Cortés-Arcas MV, Puig M, et al. Impact of the new american and british guidelines on the management and treatment of dyslipidemia in a spanish working population. Rev Esp Cardiol 2014;67:906-911 [T,I]

25278212             R/C

IMPACT OF THE NEW AMERICAN AND BRITISH GUIDELINES ON THE MANAGEMENT AND TREATMENT OF DYSLIPIDEMIA IN A SPANISH WORKING POPULATION

 

Lobos JM, Galve E, Royo-Bordonada MA, Alegría E, Armario P, Brotons C, et al; en nombre del Comité Español Interdisciplinario de Prevención Cardiovascular y de la Sociedad Española de Cardiología. Posicionamiento del Comité Español Interdisciplinario de Prevención Cardiovascular y la Sociedad Española de Cardiología en el tratamiento de las dislipemias. Divergencia entre las guías europea y estadounidense. Rev Esp Cardiol 2014;67:913-919 [M,III]

25091935             R/C

POSICIONAMIENTO DEL COMITÉ ESPAÑOL INTERDISCIPLINARIO DE PREVENCIÓN CARDIOVASCULAR Y LA SOCIEDAD ESPAÑOLA DE CARDIOLOGÍA EN EL TRATAMIENTO DE LAS DISLIPEMIAS. DIVERGENCIA ENTRE LAS GUÍAS EUROPEA Y ESTADOUNIDENSE

 

SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE

Rørtveit G. Research networks in primary care: An answer to the call for better clinical research. Scand J Prim Health Care 2014;32:107-109 [AO,I]

25110911

REDES DE INVESTIGACIÓN EN ATENCIÓN PRIMARIA: RESPUESTA A LA LLAMADA A UNA MEJOR INVESTIGACIÓN CLÍNICA

 

Bekkelund SI, Ofte HK, Alstadhaug KB. Patient satisfaction with conventional, complementary, and alternative treatment for cluster headache in a Norwegian cohort. Scand J Prim Health Care 2014;32:111-116 [S,I]

25116790             R/C

SATISFACCIÓN DEL PACIENTE CON EL TRATAMIENTO CONVENCIONAL, COMPLEMENTARIO Y ALTERNATIVO DE LA CEFALEA EN RACIMOS EN UNA COHORTE NORUEGA

 

Prins MA, Verhaak PF, Smit D, Verheij RA. Healthcare utilization in general practice before and after psychological treatment: a follow-up data linkage study in primary care. Scand J Prim Health Care 2014;32:117-123 [S,II]

25142308             R/C

UTILIZACIÓN DE LA ATENCIÓN SANITARIA EN MEDICINA GENERAL ANTES Y DESPUÉS DE TRATAMIENTO PSICOLÓGICO: ESTUDIO DE SEGUIMIENTO DE ENLACE DE DATOS EN ATENCIÓN PRIMARIA

 

van Doorn-Klomberg AL, Braspenning JC, Wolters RJ, Bouma M, de Grauw WJ, Wensing M. Organizational determinants of high-quality routine diabetes care. Scand J Prim Health Care 2014;32:124-131 [T,II]

25264939             R/C

DETERMINANTES ORGANIZATIVOS DE LA ATENCIÓN RUTINARIA DE ALTA CALIDAD EN DIABETES

 

Axelsdottir TO, Sigurdsson EL, Gudmundsdottir AM, Kristjansdottir H, Sigurdsson JA. Drug use during early pregnancy: Cross-sectional analysis from the Childbirth and Health Study in Primary Care in Iceland. Scand J Prim Health Care 2014;32:139-145 [T,I]

25299613             R/C

USO DE FÁRMACOS DURANTE EL EMBARAZO TEMPRANO: ANÁLISIS TRANSVERSAL DEL ESTUDIO CHILDBIRTH AND HEALTH EN ATENCIÓN PRIMARIA EN ISLANDIA

 

THE LANCET

Reznik Y, Cohen O, Aronson R, Conget I, Runzis S, Castaneda J, et al; OpT2mise Study Group. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet 2014;384:1265-1272 [EC,I]

24998009             R/C

TRATAMIENTO CON BOMBA DE INSULINA COMPARADO CON LAS INYECCIONES DIARIAS MÚLTIPLES PARA EL TRATAMIENTO DE LA DIABETES TIPO 2 (OPT2MISE): ENSAYO CONTROLADO ALEATORIZADO SIN ENMASCARAR

 

MannJ, McLean R, Skeaff M, Morenga LT. Low carbohydrate diets: going against the grain. Lancet 2014; 384: 1479-1480 [AO,I]

DIETAS BAJAS EN CARBOHIDRATOS: IR CONTRA EL GRANO

 

Health inequities in the USA: closing the gaps. Lancet 2014;384:1478 [AO,I]

DESIGUALDADES SANITARIAS EN EE UU: CERRAR LOS HUECOS

 

Hwang SW, Burns T.  Health interventions for people who are homeless. Lancet 2014; 384: 1541-1547 [R,I]

INTERVENCIONES SANITARIAS EN PERSONAS SIN HOGAR

 

McIntyre PB, Clark TA. Pertussis vaccine in pregnancy-first dose for every infant? Lancet 2014 [Epub ahead of print] [AO,I]

25037989

VACUNA PERTUSSIS EN EL EMBARAZO ¿PRIMERA DOSIS PARA TODOS LOS NIÑOS?

 

Iannaccone A, Zarbin MA. A new era in medical therapy for retinal degenerative disease? Lancet 2014 [Epub ahead of print] [AO,I]

25030841

¿UNA NUEVA ERA EN EL TRATAMIENTO MÉDICO DE LA ENFERMEDAD DEGENERATIVA DE LA RETINA?

 

THE NEW ENGLAND JOURNAL OF MEDICINE

Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371:1285-1294 [EC,I]

25196117             R/C

RETIRADA DE CORTICOIDES INHALADOS Y EXACERBACIONES DE LA EPOC

 

DeLoughery TG. Microcytic anemia. N Engl J Med 2014;371:1324-1331 [R,I]

25271605

ANEMIA MICROCÍTICA

 

Reilly JJ. Stepping down therapy in COPD. N Engl J Med 2014;371:1340-1341 [AO,I]

25196116

REDUCIR EL TRATAMIENTO EN LA EPOC

 

Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, et al; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014;371:1392-1406 [S,I]

25234206             R/C

SEGUIMIENTO DE LA BAJADA DE PRESIÓN ARTERIAL Y EL CONTROL DE LA GLUCOSA EN LA DIABETES TIPO 2

 

Baden LR, Kanapathipillai R, Campion EW, Morrissey S, Rubin EJ, Drazen JM. Ebola--an ongoing crisis. N Engl J Med 2014;371:1458-1459 [AO,I]

25237780

ÉBOLA: UNA CRISIS EN CURSO

 

Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014;371:1619-1628 [R,I]

25337751

NEUMONÍA ADQUIRIDA EN LA COMUNIDAD

 

Warner DF, Mizrahi V. Shortening treatment for tuberculosis--to basics. N Engl J Med 2014;371:1642-1643 [AO,I]

25337754

ACORTAR EL TRATAMIENTO DE LA TUBERCULOSIS: A LO BÁSICO

 

THORAX

Shaheen SO. Antioxidants and respiratory disease: the uric acid paradox. Thorax 2014;69:978-979 [AO,I]

25122087

ANTIOXIDANTES Y ENFERMEDAD RESPIRATORIA: LA PARADOJA DEL ÁCIDO ÚRICO

 

Cai Y, Schikowski T, Adam M, Buschka A, Carsin AE, Jacquemin B, et al. Cross-sectional associations between air pollution and chronic bronchitis: an ESCAPE meta-analysis across five cohorts. Thorax 2014;69:1005-1014 [M,II]

25112730             R/C

ASOCIACIONES TRANSVERSALES ENTRE CONTAMINACIÓN AÉREA Y BRONQUITIS CRÓNICA: METAANÁLISIS ESCAPE A TRAVÉS DE CINCO COHORTES

 

Horsfall LJ, Nazareth I, Petersen I. Serum uric acid and the risk of respiratory disease: a population-based cohort study. Thorax 2014;69:1021-106 [S,I]

24904021             R/C

ÁCIDO ÚRICO SÉRICO Y RIESGO DE ENFERMEDAD RESPIRATORIA: ESTUDIO DE COHORTE POBLACIONAL

 

 

 

ANNALS OF INTERNAL MEDICINE

 

S25329205         

Physical symptoms account for more than half of all outpatient visits, yet the predominant disease-focused model of care is inadequate for many of these symptom-prompted encounters. Moreover, the amount of clinician training dedicated to understanding, evaluating, and managing common symptoms is disproportionally small relative to their prevalence, impairment, and health care costs. This narrative review regarding physical symptoms addresses 4 common epidemiologic questions: cause, diagnosis, prognosis, and therapy. Important findings include the following: First, at least one third of common symptoms do not have a clear-cut, disease-based explanation (5 studies in primary care, 1 in specialty clinics, and 2 in the general population). Second, the history and physical examination alone contribute 73% to 94% of the diagnostic information, with costly testing and procedures contributing much less (5 studies of multiple types of symptoms and 4 of specific symptoms). Third, physical and psychological symptoms commonly co-occur, making a dualistic approach impractical. Fourth, because most patients have multiple symptoms rather than a single symptom, focusing on 1 symptom and ignoring the others is unwise. Fifth, symptoms improve in weeks to several months in most patients but become chronic or recur in 20% to 25%. Sixth, serious causes that are not apparent after initial evaluation seldom emerge during long-term follow-up. Seventh, certain pharmacologic and behavioral treatments are effective across multiple types of symptoms. Eighth, measuring treatment response with valid scales can be helpful. Finally, communication has therapeutic value, including providing an explanation and probable prognosis without "normalizing" the symptom.

S25155419         

The USPSTF recommends offering or referring adults who are overweight or obese and have additional CVD risk factors to intensive behavioral counseling interventions to promote a healthful diet and physical activity for CVD prevention. (B recommendation).

S25232633         

Medium- and high-intensity diet and physical activity behavioral counseling in overweight or obese persons with CVD risk factors resulted in consistent improvements across a variety of important cardiovascular intermediate health outcomes up to 2 years. High-intensity combined lifestyle counseling reduced diabetes incidence in the longer term. The applicability of these findings depends largely on the availability of intensive counseling in practice and real-world fidelity and adherence to these interventions.

 

ATENCION PRIMARIA

 

S25034722
La hiperlipidemia familiar combinada (HFC) es un trastorno muy frecuente asociado a enfermedad coronaria prematura. Se transmite de forma autosómica dominante, aunque no existe un gen único asociado al trastorno. El diagnóstico se realiza mediante criterios clínicos, y son importantes la variabilidad del fenotipo lipídico y la historia familiar de hiperlipidemia.

Es frecuente la asociación con diabetes mellitus tipo 2, hipertensión arterial y obesidad central. Los pacientes con HFC se consideran de riesgo cardiovascular alto y el objetivo terapéutico es un colesterol-LDL < 100 mg/dl, y < 70 mg/dl en presencia de enfermedad cardiovascular establecida o diabetes mellitus. Los pacientes con HFC requieren tratamiento con estatinas potentes y, a veces, tratamiento combinado. La identificación y el manejo de otros factores de riesgo cardiovascular, como la diabetes y la hipertensión, son fundamentales para reducir la carga de enfermedad cardiovascular. Este documento proporciona recomendaciones para el diagnóstico y el tratamiento integral de los pacientes con HFC especialmente dirigidas a médicos de atención primaria.

 

•- La HFC se diagnóstica mediante criterios clínicos. No hay una prueba genética de certeza.

  

•- Para el diagnóstico de la HFC se requiere la presencia de al menos 2 familiares directos con hiperlipidemia (colesterol y/o triglicéridos elevados).

  

•- Se recomienda confirmar la variabilidad fenotípica en el individuo y sus familiares mediante análisis de lípidos repetidos.

  

•- Se debe sospechar la HFC en un sujeto con hiperlipidemia primaria (c-LDL > 160 mg/dl y/o triglicéridos > 200 mg/dl).

  

•- Si está disponible, la determinación de una apo B > 120 mg/dl apoya el diagnóstico clínico.

  

•- No se deben aplicar los criterios de Framingham y SCORE para la valoración del RCV.

  

•- Los pacientes con HFC se deben considerar de alto RCV, y el objetivo en c-LDL debe ser < 100 mg/dl.

  

•- En los pacientes con HFC y ECV o DM tipo 2, el objetivo en c-LDL debe ser < 70 mg/dl.

  

•- El tratamiento farmacológico hipolipemiante se debe comenzar en el momento del diagnóstico, y la mayoría de estos pacientes requieren estatinas potentes o tratamiento combinado con ezetimiba o fibratos.

  

•- En el tratamiento combinado de estatinas y fibratos está contraindicado el uso del gemfibrozilo.

  

•- Si existe un aumento en las transaminasas, se debe realizar una ecografía hepática para descartar esteatosis hepática.

  

•- El objetivo de control glucémico en la HFC es una HbA1c < 7%, siendo menos estricto en pacientes ancianos, con riesgo de hipoglucemias o con enfermedad aterosclerótica muy avanzada (HbA1c 8-8,5%).

  

•- En los pacientes con DM tipo 2, el tratamiento inicial es metformina, y en caso necesario se pueden asociar otros fármacos, como IDDP-4 y análogos GLP-1, dado su perfil de seguridad y beneficio sobre el peso.

  

•- En los pacientes con HTA, el objetivo es una PA < 140/90 mmHg.

  

•- En los pacientes con DM, el objetivo de PAD es 80-85 mmHg, no existiendo beneficio añadido con cifras de PAS < 130 mmHg.

  

•- En la HTA se deben utilizar fármacos de acción prolongada, siendo los IECA, los ARA II y/o los antagonistas del calcio los recomendables por su efecto neutro sobre el perfil lipídico y glucémico.

S24656757 

En la población infantil y adolescente española la alimentación no saludable relacionada con la obesidad muestra un patrón socioeconómico claro.

S24559729 

La utilización de AD en la CV ha experimentado un gran incremento entre 2000-2010, mientras que el de A e H ha sido moderado, aunque su consumo todavía está por encima del de AD. A pesar de la reducción en el coste de la DDD en ambos grupos, el importe global de la factura en antidepresivos en la CV sigue en aumento.

 

BRITISH JOURNAL OF PSYCHIATRY

 

S25104834 

Beyond ADHD symptoms, the likelihood of receiving ADHD medication is predicted by social variables and not by psychiatric comorbidity or by parenting. This emphasises the need to improve global interventions by offering the same therapeutic opportunities (including medication) as those received by the rest of the population to some subgroups (i.e. immigrants) and by diminishing possible unnecessary prescriptions.

S25274315 

Psychotherapy may be effective in the treatment of subclinical depression and reduce the incidence of major depression, but more high-quality research is needed.

S25104833 

The changes may be related to economic recession and its impact on children from diverse cultural backgrounds, but may also be due to improvements in mortality registration in South America

 

BRITISH MEDICAL JOURNAL

 

S25281681  

Our analysis shows that the findings obtained from industry sponsored statin trials seem similar in magnitude as those in non-industry sources. There are actual differences in the effectiveness of individual statins at various doses that explain previously observed discrepancies between industry and non-industry sponsored trials.

S25269649  

Adherence to a low risk lifestyle before pregnancy is associated with a low risk of gestational diabetes and could be an effective strategy for the prevention of gestational diabetes.

S25249162  

From 1991 to 2012, more than one in 10 first line antibiotic monotherapies for the selected infections were associated with treatment failure. Overall failure rates increased by 12% over this period, with most of the increase occurring in more recent years, when antibiotic prescribing in primary care plateaued and then increased.

S25359996  

In older patients receiving angiotensin converting enzyme inhibitors or angiotensin receptor blockers, co-trimoxazole is associated with an increased risk of sudden death. Unrecognized severe hyperkalemia may underlie this finding. When appropriate, alternative antibiotics should be considered in such patients.

S25335825  

Adolescents who self harm seem to be vulnerable to a range of adverse outcomes in early adulthood. Risks were generally stronger in those who had self harmed with suicidal intent, but outcomes were also poor among those who had self harmed without suicidal intent. These findings emphasise the need for early identification and treatment of adolescents who self harm.

S25274009  

Long acting insulin analogs are probably superior to intermediate acting insulin analogs, although the difference is small for hemoglobin A1c. Patients and their physicians should tailor their choice of insulin according to preference, cost, and accessibility.

S25352269  

High milk intake was associated with higher mortality in one cohort of women and in another cohort of men, and with higher fracture incidence in women. Given the observational study designs with the inherent possibility of residual confounding and reverse causation phenomena, a cautious interpretation of the results is recommended.

 

CANADIAN MEDICAL ASSOCIATION JOURNAL

 

S25246411 

In this longitudinal population-based study, metformin use was associated with an increased incidence of low TSH levels in patients with treated hypothyroidism, but not in euthyroid patients. The clinical consequences of this need further investigation.

S25225226 

We found that quality improvement strategies for coordination of care reduced hospital admissions among patients with chronic conditions other than mental illness and reduced emergency department visits among older patients. Our results may help clinicians and policy-makers reduce utilization through the use of strategies that target the system (team changes, case management) and the patient (promotion of self-management).

 

CIRCULATION

 

S25208551 

Numbers of AF-related incident ischemic strokes at age =80 years have trebled over the last 25 years, despite the introduction of anticoagulants, and are projected to treble again by 2050, along with the numbers of systemic emboli. Improved prevention in older people with AF should be a major public health priority.

S25161044

The once-settled roles of all dietary fatty acid classes vis-à-vis coronary heart disease (CHD) seem to be under fire these days. For decades it had been received wisdom that "saturated fats are bad," and that margarines should replace butter to reduce risk for heart attacks. But a recent Time magazine cover that screamed, "EAT BUTTER" illustrates this changing perspective1. Olive oil, the poster child of the "Mediterranean Diet" and a rich source of oleic acid, has long been nearly worshiped as cardioprotective, but recent meta-analyses2 and animal feeding studies3 are challenging this view. Similarly, the marine-derived omega-3 fatty acids, which have historically found a place among the "healthiest" of all dietary fats have fallen on hard times based on the null findings in several recent randomized trials4, and now linoleic acid (LA), the principal vegetable-oil derived omega-6 fatty acid - once taken as a medicine by the tablespoon to lower cholesterol - is now being accused of causing, not preventing heart disease5. The only class that seems to be holding its own is the industrially-produced trans fats which, although clearly promoting CHD, are also slowly disappearing from the American diet6. Understandably, the American public is becoming jaded when it comes to official proclamations of what constitutes a "healthy fat."

S25189213 

-In the context of balanced primary and secondary endpoints, saxagliptin treatment was associated with an increased risk for hospitalization for heart failure. This increase in risk was highest among patients with elevated levels of natriuretic peptides, prior heart failure, or chronic kidney disease. Clinical Trial Registration Information-ClinicalTrials.gov. Identifier: NCT01107886.

S25189212 

The diabetes pandemic is currently among the most challenging non-communicable disease threats to public health. It is estimated that 382 million people worldwide have diabetes and the majority will likely die from cardiovascular disease. Diabetes is an independent risk factor for atherosclerotic cardiovascular disease as well as heart failure, with a 5-fold increased risk of heart failure in women with diabetes and a 2.4-fold increased risk in men.1-3 In patients with diabetes, the prevalence of heart failure is between 10 to 22%, 4 times higher than that of the general population.2 The degree of glycemic control in patients with diabetes has been demonstrated to be associated with the risk of atherosclerotic cardiovascular disease and new onset heart failure.1,4 It has been a widely held belief that lowering HbA1c levels with glucose-lowering medications in patients with diabetes would result in clinical benefits, including the reduction of atherosclerotic cardiovascular events. Lowering of the HbA1c levels by glucose-lowering medications in patients with diabetes mellitus has been used as a surrogate measure of their benefit including the potential to reduce cardiovascular risk by clinicians, guideline writing groups, and regulators.5.

 

DIABETES CARE

 

S25011946 

Adding exenatide to titrated glargine with metformin resulted in similar glycemic control as adding lispro and was well tolerated. These findings support exenatide as a noninsulin addition for patients failing basal insulin.

S25078900 

Gla-300 controls HbA1c as well as Gla-100 for people with type 2 diabetes treated with basal and mealtime insulin but with consistently less risk of nocturnal hypoglycemia.

S25249670 

These findings provide, in a large, multicenter data set, objective evidence that testing outside guidance on HbA1c monitoring frequency is associated with a significant detrimental effect on diabetes control. To achieve the optimum downward trajectory in HbA1c, monitoring frequency should be quarterly, particularly in cases with suboptimal HbA1c. While this impact appears small, optimizing monitoring frequency across the diabetes population may have major implications for diabetes control and comorbidity risk.

S25249673 

We performed a review of the literature to determine whether the dipeptidyl peptidase-4 inhibitors (DPP4-I) may have the capability to directly and positively influence diabetic microvascular complications. The literature was scanned to identify experimental and clinical evidence that DPP4-I can ameliorate diabetic microangiopathy. We retrieved articles published between 1 January 1980 and 1 March 2014 in English-language peer-reviewed journals using the following terms: ("diabetes" OR "diabetic") AND ("retinopathy" OR "retinal" OR "nephropathy" OR "renal" OR "albuminuria" OR "microalbuminuria" OR "neuropathy" OR "ulcer" OR "wound" OR "bone marrow"); ("dipeptidyl peptidase-4" OR "dipeptidyl peptidase-IV" OR "DPP-4" OR "DPP-IV"); and ("inhibition" OR "inhibitor"). Experimentally, DPP4-I appears to improve inflammation, endothelial function, blood pressure, lipid metabolism, and bone marrow function. Several experimental studies report direct potential beneficial effects of DPP4-I on all microvascular diabetes-related complications. These drugs have the ability to act either directly or indirectly via improved glucose control, GLP-1 bioavailability, and modifying nonincretin substrates. Although preliminary clinical data support that DPP4-I therapy can protect from microangiopathy, insufficient evidence is available to conclude that this class of drugs directly prevents or decreases microangiopathy in humans independently from improved glucose control. Experimental findings and preliminary clinical data suggest that DPP4-I, in addition to improving metabolic control, have the potential to interfere with the onset and progression of diabetic microangiopathy. Further evidence is needed to confirm these effects in patients with diabetes.

S25249668 

As diabetes develops, we currently waste the first ~10 years of the natural history. If we found prediabetes and early diabetes when they first presented and treated them more effectively, we could prevent or delay the progression of hyperglycemia and the development of complications. Evidence for this comes from trials where lifestyle change and/or glucose-lowering medications decreased progression from prediabetes to diabetes. After withdrawal of these interventions, there was no "catch-up"-cumulative development of diabetes in the previously treated groups remained less than in control subjects. Moreover, achieving normal glucose levels even transiently during the trials was associated with a substantial reduction in subsequent development of diabetes. These findings indicate that we can change the natural history through routine screening to find prediabetes and early diabetes, combined with management aimed to keep glucose levels as close to normal as possible, without hypoglycemia. We should also test the hypothesis with a randomized controlled trial.

S24989706 

Even in this high-risk group, vascular calcification and known CVD risk factors provide useful information for ongoing assessment. The use of cholesterol-lowering medication seemed to be protective for mortality.

S25249672 

The incidence and prevalence of diabetes mellitus have grown significantly throughout the world, due primarily to the increase in type 2 diabetes. This overall increase in the number of people with diabetes has had a major impact on development of diabetic kidney disease (DKD), one of the most frequent complications of both types of diabetes. DKD is the leading cause of end-stage renal disease (ESRD), accounting for approximately 50% of cases in the developed world. Although incidence rates for ESRD attributable to DKD have recently stabilized, these rates continue to rise in high-risk groups such as middle-aged African Americans, Native Americans, and Hispanics. The costs of care for people with DKD are extraordinarily high. In the Medicare population alone, DKD-related expenditures among this mostly older group were nearly $25 billion in 2011. Due to the high human and societal costs, the Consensus Conference on Chronic Kidney Disease and Diabetes was convened by the American Diabetes Association in collaboration with the American Society of Nephrology and the National Kidney Foundation to appraise issues regarding patient management, highlighting current practices and new directions. Major topic areas in DKD included 1) identification and monitoring, 2) cardiovascular disease and management of dyslipidemia, 3) hypertension and use of renin-angiotensin-aldosterone system blockade and mineralocorticoid receptor blockade, 4) glycemia measurement, hypoglycemia, and drug therapies, 5) nutrition and general care in advanced-stage chronic kidney disease, 6) children and adolescents, and 7) multidisciplinary approaches and medical home models for health care delivery. This current state summary and research recommendations are designed to guide advances in care and the generation of new knowledge that will meaningfully improve life for people with DKD.

S25024396 

Two-year weight loss was the strongest predictor of reduced diabetes risk and improvements in cardiometabolic traits.

S25048383 

Once-weekly albiglutide therapy in renally impaired patients with type 2 diabetes provided statistically superior glycemic improvement with almost similar tolerability compared with daily sitagliptin therapy.

 

DRUGS

 

S25239267         

Antiepileptic drugs (AEDs) are a class of medications that have received considerable attention as possible treatments for agitation and aggression in patients with dementia. This attention has been driven in equal measure by promising findings from limited trial and observational data and the desire to find treatments with improved tolerability. Their use, to date, has been largely confined to circumstances where first-line treatments have proven inadequate or are poorly tolerated. In recent years there has been some growth in the evidence base, and we can now make more informed recommendations regarding a number of older AEDs. Carbamazepine continues to have the best evidence to support its use, although the evidence base remains relatively small and concerns regarding tolerability limit its use. There is now more consistent evidence that valproate preparations should not be used for agitation and aggression in dementia. Despite a lack of high-quality data, some results have been reported for several newer medications, including levetiracetam, oxcarbazepine, gabapentin, topiramate and lamotrigine, and a number of these warrant further investigation. Recent findings and implications for clinical practice are discussed.

S25315029         

The humanized monoclonal antibody bevacizumab (Avastin(®)) has been available in the EU since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to antineoplastic agents improves progression-free survival and/or overall survival in patients with advanced cancer, including when used as first- or second-line therapy in metastatic colorectal cancer, as first-line therapy in advanced nonsquamous non-small cell lung cancer, as first-line therapy in metastatic renal cell carcinoma, as first-line therapy in metastatic breast cancer, and as first-line therapy in epithelial ovarian, fallopian tube or primary peritoneal cancer or in recurrent, platinum-sensitive or platinum-resistant disease. Results of these studies are supported by the findings of routine oncology practice studies conducted in real-world settings. The tolerability profile of bevacizumab is well defined and adverse events associated with its use (e.g. hypertension, proteinuria, haemorrhage, wound healing complications, arterial thromboembolism, gastrointestinal perforation) are generally manageable. In conclusion, bevacizumab remains an important option for use in patients with advanced cancer.

S25270377         

Dabigatran etexilate (Pradaxa(®), Prazaxa(®)) has recently been approved for the treatment of acute venous thromboembolism (VTE) and prevention of VTE recurrence. Dabigatran etexilate is an oral prodrug of dabigatran, a selective, reversible, competitive, direct thrombin inhibitor. Dabigatran etexilate has a wide therapeutic range that allows for fixed-dose administration without the need for routine monitoring, a requirement of standard vitamin K antagonist (VKA) therapy. In randomized phase III trials in patients with acute VTE (RE-COVER and RE-COVER II), long-term treatment with oral dabigatran etexilate 150 mg twice daily for 6 months after initial parenteral anticoagulation was noninferior to dose-adjusted warfarin with regard to the incidence of recurrent symptomatic VTE or related death. In randomized trials of patients with previously treated VTE, extended dabigatran etexilate treatment was noninferior to warfarin (RE-MEDY) and significantly more effective than placebo (RE-SONATE) with regard to the incidence of recurrent VTE or related death. Dabigatran etexilate was generally well tolerated, with a similar incidence of major bleeding to that with warfarin in individual studies (although pooled data showed a significantly lower incidence in patients with acute VTE), and significantly lower incidences of the combined endpoint of major or clinically relevant nonmajor bleeding and of any bleeding than with warfarin. However, in the RE-SONATE trial, dabigatran etexilate was associated with a higher risk of bleeding than placebo. In conclusion, dabigatran etexilate is a valuable treatment option for acute VTE and prevention of VTE recurrence, providing an effective and convenient alternative to standard VKA therapy with the potential for a lower overall rate of bleeding.

S25274537         

Oral empagliflozin (Jardiance(®)), a sodium glucose cotransporter-2 (SGLT2) inhibitor, is a convenient once-daily treatment for adult patients with type 2 diabetes mellitus. By inhibiting reabsorption of glucose from the proximal tubules in the kidney via inhibition of SGLT2, empagliflozin provides a novel insulin-independent mechanism of lowering blood glucose. In several phase III trials (=104 weeks' duration; typically 24 weeks' duration) and extension studies (typically =76 weeks' treatment), empagliflozin monotherapy or add-on therapy to other antihyperglycaemics, including insulin, improved glycaemic control and reduced bodyweight and systolic blood pressure in adult patients with type 2 diabetes. In a large phase III trial, as add-on therapy to metformin, empagliflozin was shown to be noninferior to glimepiride at 52 and 104 weeks and superior to glimepiride at 104 weeks, in terms of reductions in glycated haemoglobin level (primary endpoint). Empagliflozin was well tolerated by participants in these clinical trials, with most adverse events being mild or moderate in intensity. Empagliflozin treatment appeared to have no intrinsic risk of hypoglycaemia, although hypoglycaemia occurred more frequently when empagliflozin was coadministered with insulin and/or a sulfonylurea. With its insulin-independent mechanism of action, empagliflozin monotherapy or combination therapy with other antidiabetic drugs, including insulin, provides a useful addition to the therapeutic options for the management of type 2 diabetes. This article reviews the pharmacological properties and clinical use of empagliflozin in patients with type 2 diabetes.

S25297911         

Linagliptin (Trajenta(®), Tradjenta(®)) is a dipeptidyl peptidase (DPP)-4 inhibitor approved for the treatment of adults with type 2 diabetes mellitus in several countries. A fixed-dose combination of linagliptin/metformin (Jentadueto(®)) is also available. This article reviews the pharmacology, therapeutic efficacy and tolerability of linagliptin in the management of type 2 diabetes, with the aim of updating its place in therapy based on recently published data. In randomized, controlled trials, oral linagliptin 5 mg once daily (or 2.5 mg twice daily when combined with metformin) improved glycaemic control when used alone or in combination with other antidiabetic agents, including metformin, a sulfonylurea, thiazolidinedione or insulin. Improvements in glycaemic control were also shown in patients with renal impairment, including severe impairment, and the elderly (aged =70 years). Linagliptin is the first DPP-4 inhibitor to be eliminated primarily via a nonrenal route, enabling its use without dosage adjustment in patients with any degree of renal impairment. Linagliptin is generally well tolerated and, as with other DPP-4 inhibitors, it is associated with a low risk of hypoglycaemia and has no effect on bodyweight. Some data indicate that linagliptin may have beneficial effects on cardiovascular and renal safety profiles in patients with type 2 diabetes, but more data are needed. Meanwhile, the low risk of hypoglycaemia and the nonrenal route of elimination may provide important advantages for some patient groups, including elderly or renally impaired patients.

S25255924         

Despite their transfusion-independence, non-transfusion-dependent thalassemia (NTDT) patients experience a variety of serious clinical complications that require prompt and comprehensive management. Transfusion therapy may still be an important part of management of this disease, in cases of acute stress, to support growth and development in childhood, or to prevent clinical morbidities stemming from ineffective erythropoiesis or hemolytic anemia. Although splenectomy is associated with improvements in hemoglobin levels, it leads to several short- and long-term adverse events, warranting caution in application of this intervention. Fetal hemoglobin induction therapy has been evaluated in

non-randomized studies, with benefits extending beyond hematologic improvements to lowering morbidity risk. Effective and safe iron chelation therapy is now available for NTDT patients in whom iron overload develops, irrespective of transfusions, due to increased intestinal absorption, ultimately leading to clinically high iron burden levels and subsequent morbidity. Optimal management of NTDT patients requires a holistic approach targeting all hallmarks of the disease to ensure favorable patient outcomes.

S25352391         

Oral rifaximin 550 mg (Refero®; Targaxan®; Tixteller®; Xifaxan®) twice daily, either alone or more commonly with medicines containing lactulose, is approved in several countries, including the UK, EU and USA, for use in adults with liver disease to reduce the recurrence of episodes of overt hepatic encephalopathy (HE). Rifaximin is a broad-spectrum antibacterial that acts locally in the gut to reduce intestinal flora, including ammonia-producing species, with hyperammonaemia considered to play a central role in the pathogenesis of HE. In a 6-month, multinational trial in patients with liver disease, rifaximin 550 mg twice daily (± lactulose) was an effective and well tolerated treatment for reducing the recurrence of HE episodes. At study end, rifaximin therapy significantly prolonged the time to the first breakthrough HE episode compared with placebo (± lactulose), irrespective of geographical region or baseline patient and disease characteristics. Rifaximin treatment also significantly reduced HE-related hospitalizations and improved health-related quality of life compared with placebo. Furthermore, the efficacy of rifaximin with or without lactulose in reducing the recurrence of overt HE episodes was maintained after up to 2.5 years of treatment, with no new safety signals arising during this period. This article reviews the pharmacology and therapeutic efficacy of rifaximin 550 mg twice daily in reducing the recurrence of overt HE episodes in adults with liver disease.

S25288321         

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are currently among the most commonly prescribed pharmaceutical agents worldwide. Apart from their well-established therapeutic value in cardiovascular disease, there is a long-standing debate on their potential association with cancer. To obtain and discuss the existing clinical evidence, an overview of meta-analysis articles addressing this issue was carried out. As of today, the accumulated evidence does not support the hypothesis that statins affect the risk of developing cancer, when they are taken at low doses for managing hypercholesterolaemia. However, current data cannot exclude an increased cancer risk in elderly patients associated with hydrophilic statin use, or decreases in the risks of certain cancers, such as gastric, oesophageal, liver, colorectal and advanced/aggressive prostate cancer. On the other hand, some recent observational studies have provided evidence that statins might be useful in modifying the prognosis of patients diagnosed with malignancy. Until a definitive benefit is demonstrated in randomized controlled trials, statins cannot be recommended either for cancer prevention or for modifying cancer-related outcomes. Further research is warranted to clarify the potential role(s) of statins in the prevention and treatment of cancer.

S25204470         

The prevalence of use of long-term systemic glucocorticoid therapy in the general adult population is 1 %. This figure increases to up to 3 % in elderly women. Metabolic (i.e. diabetes mellitus, dyslipidemia, weight gain, lipodystrophy) and cardiovascular (i.e. hypertension, cardiovascular events) adverse events are commonly observed in these patients and can be life threatening. Paradoxically, there is very few data on some of these adverse events and many of the available studies remain inconclusive. Incidence of and risk factors for dyslipidemia, weight gain and lipodystrophy are poorly defined. The optimal treatment plan for patients diagnosed with glucocorticoid-induced diabetes or hypertension is undetermined. Finally, there is no medical consensus on the best strategies for the prevention and detection of these complications. However, certain of these questions can be answered by looking at available data on patients with endogenous hypercortisolism (i.e. Cushing's syndrome). This article reviews the pathophysiology, incidence, risk factors, screening, and treatment of glucocorticoid-induced weight gain, lipodystrophy, diabetes, dyslipidemia, hypertension, and

cardiovascular events. It also focuses on the possible prevention of these adverse events by targeting the glucocorticoid receptor using selective glucocorticoid receptor modulators.

S25300412         

The long-acting anticholinergic agent tiotropium bromide (Spiriva(®)) is available as a solution for inhalation via Respimat(®) Soft Mist™ Inhaler in the EU and various other countries for the treatment of chronic obstructive pulmonary disease (COPD). With the Respimat(®) Soft Mist™ Inhaler there is improved lung deposition of drug (allowing a reduced dosage compared with tiotropium HandiHaler(®)), the delivered drug dose is independent of inspiratory effort and the prolonged duration of the aerosol cloud should make the co-ordination of actuation and inhalation easier. In patients with COPD, tiotropium Respimat(®) improved lung function, COPD exacerbations, health-related quality of life and dyspnoea and was at least as effective as tiotropium HandiHaler(®). Tiotropium Respimat(®) was generally well tolerated in patients with COPD, with anticholinergic adverse events among the most commonly reported adverse events. In the TIOSPIR trial, tiotropium Respimat(®) was noninferior to tiotropium HandiHaler(®) in terms of all-cause mortality, and the risk of cardiovascular mortality or major adverse cardiovascular events did not significantly differ between the two treatment groups. In conclusion, tiotropium Respimat(®) Soft Mist™ Inhaler is a useful option for the treatment of patients with COPD.

 

EUROPEAN HEART JOURNAL

 

S24944329         

Younger patients with heart failure have different clinical characteristics including different aetiologies, more severe left ventricular dysfunction, and less severe symptoms. Three-year mortality rates are lower for all age groups under 60 years compared with older patients.

 

FAMILY MEDICINE

 

S25275276  

This limited descriptive study offers insight into the financial status of GH programs. Despite institutional support, respondents relied on personal funds and were pessimistic about future funding.

S25275280  

This is the 33rd annual report prepared by the American Academy of Family Physicians (AAFP) that reports retrospectively the percentage of graduates from US MD and DO-granting medical schools who entered an Accreditation Council for Graduate Medical Education (ACGME)-accredited family medicine residency program and covers the period between July 2013 and June 2014. Approximately 8.5% of the 18,384 graduates of US MD-granting medical schools entered family medicine in 2014. Seventy of the 130 US LCME-accredited medical schools produced 80% of the graduates who entered family medicine. Schools that received public funding and schools with a department or division of family medicine had higher percentages of students selecting family medicine. Schools are ranked based upon a 3-year rolling average for the percentage of their graduates who entered family medicine. The West North Central, Mountain, and Pacific regions reported the highest percentages of medical school graduates who were first-year residents in family medicine programs (13.3%, 11.8%, and 11.8% respectively).

S25275281  

The 2014 National Residency Matching Program® results reveal that the number of family medicine positions offered in the Match® by programs accredited by the Accreditation Council on Graduate Medical Education has increased compared to 2013 (3,132 versus 3,062), while the total of all other primary care specialties combined has remained unchanged (784). The number of US seniors matching into family medicine also increased in 2014 over the prior year (1,416 versus 1,374). The percentage of US seniors who matched into family medicine programs grew modestly in 2014 compared to 2013 (8.6% versus 8.4%). Approximately four out of five primary care positions offered in the Match are in family medicine residency programs (3,132 versus 784). Similarly, three out of four US seniors matching into a primary care specialty match into a family medicine program (1,416 versus 520). By way of comparison, nearly five times the number of US seniors matched into family medicine as compared to medicine-pediatrics, the next largest primary care specialty.

 

FAMILY PRACTICE

 

S25121977 

This study shows that an antidepressant cessation advice given to patients (and their FPs) with inappropriate long-term antidepressant usage, albeit not effective, does seem to result in a reduction of societal costs. This reduction in costs is mostly due to reduction of productivity losses, possibly due to patient empowerment and loss of stigma.

S25135953 

Our results-most notably regarding the demand-satisfying attitude of responding GPs-call into question the classical view of the guidance and gatekeeper role of GPs in the Dutch health care system.

S25080507 

Findings from this study have implications for understanding how families blend emotion-based and problem-focused coping strategies in the face of a CRC diagnosis. Further developing evidence-based interventions that target coping and well-being in cancer patients and extending them to family members is necessary and holds great promise for providers who care for patients with familial cancers.

S24939655 

Despite these barriers, GPs are willing to ask adolescents about their cannabis use. An adolescent's awareness, environment and receptiveness favour a sustainable therapeutic relationship. Brief intervention is a tool that may be of assistance in this relationship and allow GPs to take the initiative.

S25216664 

Available evidence suggests that strong primary care in terms of adequate primary care physician supply and long-term relationships between primary care physicians and patients reduces hospitalizations for chronic ACSCs. There is a lack of evidence for the positive effects of many other organizational primary care aspects, such as specific disease management programs.

S24997249 

In the case of unwanted pregnancy, discussion of all options in a protocolized way by the GP may support patients in their decision-making. Additional training of GPs may enhance awareness of the possible benefits of abortion counselling for the patients.

S25037854 

Among patients with uncomplicated acute bronchitis and discoloured sputum, the CRP concentrations at presentation are not helpful for predicting symptom resolution.

S24987022 

This study quantifies the relative impact of 13 common chronic conditions on HRQL in a UK-based community-dwelling ageing population. Findings indicate that osteoarthritis, depression and neurological disease have a strong clinically important negative effect on HRQL. These findings may help clinical decision making and priority setting for management of individuals with multimorbidity.

S24987023 

There is a high prevalence of patients consulting GPs for abdominal pain. The review identified a comparably high rate of acute underlying diseases in need of further investigation or therapy. At the same time, the underlying cause of the complaints often remains unexplained. Further symptom-evaluating studies are necessary, ideally using standardized methodology in order to gain sufficient evidence for developing much-needed guidelines and decision support tools.

 

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

 

S25335150  

Immediate antimicrobial therapy with trimethoprim-sulfamethoxazole, nitrofurantoin, or fosfomycin is indicated for acute cystitis in adult women. Increasing resistance rates among uropathogens have complicated treatment of acute cystitis. Individualized assessment of risk factors for resistance and regimen tolerability is needed to choose the optimum empirical regimen.

 

JAMA INTERNAL MEDICINE

 

S25111880  

These 2 randomized clinical trials do not support the findings from observational research. Contrary to the results from observational studies, we found that 3 to 4 years of bisphosphonate treatment did not decrease the risk of invasive postmenopausal breast cancer.

S25133746  

A substantial proportion of the US population with limited life expectancy received prostate, breast, cervical, and colorectal cancer screening that is unlikely to provide net benefit. These results suggest that overscreening is common in both men and women, which not only increases health care expenditure but can lead to net patient harm.

S25173681  

These findings from real-world clinical practice indicate that the effectiveness of carvedilol and metoprolol succinate in patients with HF is similar.

S25179639  

Although a steady improvement in AHEI-2010 was observed across the 12-year period, the overall dietary quality remains poor. Better dietary quality was associated with higher socioeconomic status, and the gap widened with time. Future efforts to improve nutrition should address these disparities.

 

JAMA PSYCHIATRY

 

S25142196  

Cognitive therapy combined with ADM treatment enhances the rates of recovery from MDD relative to ADMs alone, with the effect limited to patients with severe, nonchronic depression.

S25133759  

Our results indicate that poor subjective sleep quality is associated with increased risk for death by suicide 10 years later, even after adjustment for depressive symptoms. Disturbed sleep appears to confer considerable risk, independent of depressed mood, for the most severe suicidal behaviors and may warrant inclusion in suicide risk assessment frameworks to enhance detection of risk and intervention opportunity in late life.

 

MEDICINA CLINICA

 

S24378145 

Durante los primeros años del funcionamiento del PDPCM (2002-2006) los casos de cáncer de intervalo representaron un porcentaje bajo (5,8%) respecto el total de CM diagnosticados en mujeres de 50 a 69 años en la provincia de Girona.

S24461737 

La cocaína es la segunda droga ilegal más consumida en el mundo occidental, tras el cannabis. Desde 1998 es la droga que más asistencias genera en los diferentes dispositivos asistenciales de urgencias, siendo responsable de más del 60% de las urgencias directamente relacionadas con el consumo de drogas. Este trabajo revisa los principales artículos científicos españoles publicados en los últimos 10 años, en los que se han analizado diferentes factores relacionados con el uso que hacen los consumidores de cocaína de los servicios de urgencias. Se incluyeron 8.795 pacientes (intervalo 57-1.755), con una edad media (DE) de 32,64 (3,02) años y un porcentaje medio de positivos a cocaína del 54,78 (47,03) %; hubo 7 trabajos con el 100% de sujetos positivos a cocaína. El sexo varón predominaba, con una media del 78,69 (12) %. Presentaron síntomas cardiovasculares el 30 (22,7) %, neurológicos el 11,6 (4,28) %, y psiquiátricos el 49,32 (23,87) %. Hubo policonsumo en el 49,02% de los pacientes (intervalo 4,3-76,2), asociado fundamentalmente a alcohol (media de 57,78 [6,18] %) y cannabis (21,56 [10,72] %). Precisaron ingreso 246 pacientes (2,8%), y 8 fallecieron (0,09%).

S24378144 

La entrevista motivacional resulta más eficaz que el abordaje habitual para reducir los errores de medicación en pacientes con polifarmacia mayores de 65 años.

S24703416 

Ni Omron ni triple toma tienen una buena concordancia con doppler, por lo que los primeros no parecen adecuados para el cribado de AP en las consultas de atención primaria.

S24210982 

En pacientes con EPOC y obstrucción grave al flujo aéreo, la puntuación en el CAT refleja un impacto de la enfermedad moderado-grave y no permite predecir la gravedad de la EPOC evaluada según el índice BODE.

 

REVISTA ESPAÑOLA DE CARDIOLOGIA

 

S25278212  

La nuevas recomendaciones supondrían identificar a más pacientes de alto riesgo y tratar con hipolipemiantes a más población que con las recomendaciones europeas, lo que aumentaría los costes.

S24835599  

La digoxina no se asoció a un aumento de la mortalidad por cualquier causa, la supervivencia libre de hospitalización por cualquier causa ni la supervivencia libre de hospitalización por causas cardiovasculares, con independencia de la presencia de insuficiencia cardiaca subyacente.

S25091935  

La publicación en Estados Unidos de la guía de 2013 de American College of Cardiology/American Heart Association para el tratamiento del colesterol elevado ha tenido gran impacto por el cambio de paradigma que supone. El Comité Español Interdisciplinario de Prevención Cardiovascular y la Sociedad Española de Cardiología han revisado esa guía, en comparación con la vigente guía europea de prevención cardiovascular y de dislipemias.

El aspecto más destacable de la guía estadounidense es el abandono de los objetivos de colesterol unido a lipoproteínas de baja densidad, de modo que proponen el tratamiento con estatinas en cuatro grupos de riesgo aumentado. En pacientes con enfermedad cardiovascular establecida, ambas guías conducen a una estrategia terapéutica similar (estatinas potentes, dosis altas). Sin embargo, en prevención primaria, la aplicación de la guía estadounidense supondría tratar con estatinas a un número de personas excesivo, particularmente de edades avanzadas. Abandonar la estrategia según objetivos de colesterol, fuertemente arraigada en la comunidad científica, podría tener un impacto negativo en la práctica clínica y crear cierta confusión e inseguridad entre los profesionales y quizá menos seguimiento y adherencia de los pacientes. Por todo ello, el presente documento reafirma las recomendaciones de la guía europea. Ambas guías tienen aspectos positivos pero, en general y mientras no se resuelvan las dudas planteadas, la guía europea, además de utilizar tablas basadas en la población autóctona, ofrece mensajes más apropiados para el entorno español y previene del posible riesgo de sobretratamiento con estatinas en prevención primaria.

S25262131  

La enfermedad cardiovascular es el principal problema de salud en Europa y el resto del mundo y la primera causa de mortalidad y gasto sanitario. Las estrategias de prevención tienen un papel fundamental en el paciente que ha tenido un síndrome coronario agudo, pues consiguen un declive en la mortalidad de estos pacientes y una reducción en la recurrencia de eventos isquémicos. Sin embargo, estas estrategias de prevención, que se han centrado en la población de alto riesgo con gran éxito, deben utilizarse también para la población general, en la que se está observando un incremento en la prevalencia de obesidad, diabetes mellitus y otras comorbilidades que pueden invertir la tendencia. En este artículo se pretende hacer una puesta al día sobre las principales medidas de prevención cardiovascular, especialmente las novedades aparecidas en el último año, y las particularidades de dichas medidas cuando se orientan al paciente que ha presentado un síndrome coronario agudo.

 

SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE

 

S25264939  

In routine primary care, it was found that favorable healthcare organization was associated with a number of intermediate outcomes in diabetes care. This finding lends support to the findings of trials on organizational changes in diabetes care. Notably, the composite measure of organizational determinants had most impact.

S25142308  

After psychological treatment, patients contact their GPs less often and present fewer psychological or social problems. Although contact rates seem to decrease, clients of psychologists are still frequent GP attenders.

S25116790  

About two-thirds of CH patients were satisfied with treatment from either GPs or neurologists, and about one-third had used CAM. Despite experiencing diagnostic delay and severe pain, cluster patients seem in general to be satisfied with doctors' conventional treatment.

S25299613  

Use of analgesics and psychotropic drugs seems common in pregnancy. Our results indicate that lack of a support network, stressful life events, and lower status in society may predispose women to more drug use. GPs and midwives responsible for maternity care could take this into account when evaluating risk and gain for women and foetuses in the primary care setting.

 

THORAX

 

S24904021 

Low levels of serum uric acid are associated with higher rates of COPD and lung cancer in current smokers after accounting for conventional risk factors.

S25112730 

Results do not show consistent associations between chronic bronchitis symptoms and current traffic-related air pollution in adult European populations.

 

THE LANCET

 

S24998009  

In patients with poorly controlled type 2 diabetes despite using multiple daily injections of insulin, pump treatment can be considered as a safe and valuable treatment option.

 

THE NEW ENGLAND JOURNAL OF MEDICINE

 

S25234206  

The benefits with respect to mortality that had been observed among patients originally assigned to blood-pressure-lowering therapy were attenuated but still evident at the end of follow-up. There was no evidence that intensive glucose control during the trial led to long-term benefits with respect to mortality or macrovascular events. (Funded by the National Health and Medical Research Council of Australia and others; ADVANCE-ON ClinicalTrials.gov number, NCT00949286.).

S25196117 

In patients with severe COPD receiving tiotropium plus salmeterol, the risk of moderate or severe exacerbations was similar among those who discontinued inhaled glucocorticoids and those who continued glucocorticoid therapy. However, there was a greater decrease in lung function during the final step of glucocorticoid withdrawal. (Funded by Boehringer Ingelheim Pharma; WISDOM ClinicalTrials.gov number, NCT00975195.).

 

 

 

 

 

                      

 

1as JART SAMFyC 2017

 


____________________________

 Para pacientes
@pontealdiaAP
 @pontealdiaURG
55 e.SAMFyC

 


 

semFYC
 

 

Estadisticas

Ver contenido por hits : 1016710



La SAMFyC:
 C/ Arriola, 4, bajo D, CP.18001 - Granada. Email: samfyc@samfyc.es; Teléfono: 958 804 201 - Fax: 958 804 202. Horario de invierno: lunes a jueves de 9:00 a 17:30 horas; viernes de 9:00 a 14:30 horas. Horario de verano: lunes a viernes de 8:00 a 15:00h. Todos los derechos reservados. Aviso Legal. 


¡CSS Válido!

Diseño web